Develops drugs for Pulmonary Arterial Hypertension.
Sep 2025Revenue $0.00/yrExpenses $51.1M/yr
No trend
Figures by year
When will Inhibikase Therapeutics be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Sep 2025, revenue was $0.00 and expenses $51.1M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2024 | $0.00 | $28.6M | −$28.6M |
| Dec 2023 | $261K | $20.4M | −$20.1M |
| Dec 2022 | $123K | $18.3M | −$18.1M |
| Dec 2021 | $3.10M | $17.9M | −$14.8M |
| Dec 2020 | $698K | $3.52M | −$2.82M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.